- The Institute
- Travel & Vaccines
- Alumni & Friends
Background and expert service
In 2000, the World Health Organization (WHO) established the World Malaria Day as an annual international day of action. Its purpose is to remind that more than three billion people in the world are at risk from malaria. The WHO and other organizations are working to roll back this infectious disease at great financial and logistical expense. This has led to a reduction in new cases in recent years. However, for the first-time last year, the WHO recorded an increase to around 230 million malaria cases worldwide, of which more than 400,000 were fatal. Children under the age of five in Africa account for more than two-thirds of the deaths. Our interview partners for journalists can be found below.
Joint major project in the fight against SARS-CoV-2
Hamburg. At the high-brilliance X-ray light source PETRA III of the German Electron Synchrotron (DESY), a research team in which the Bernhard Nocht Institute for Tropical Medicine (BNITM) is also active has identified several candidates for active agents against the coronavirus SARS-CoV-2. The promising drug candidates bind to an important protein of the virus and could thus be the basis for a drug against COVID-19.
BNITM-teams assisted in testing and sequencing patient samples
Following the request for assistance from the Ministry of Health of Guinea, the Bernhard Nocht Institute for Tropical Medicine (BNITM) sent teams to support Guinea in setting up in-country sequencing with the Oxford Nanopore MinION and to strengthen diagnostic capacity needs. The mission took place within the framework of the WHO Global outbreak alert and response network (GOARN) and the Global Health Protection Programme (GHPP) of the Federal Ministry of Health.
Which factors determine whether an infection takes a severe or mild course? This question has been occupying researchers not only since the coronavirus pandemic. In Lassa fever, the course of the disease and the chance of recovery also vary widely. A research group at the Bernhard Nocht Institute for Tropical Medicine (BNITM) found a reason in misguided immune reactions both in a mouse model of the disease as well as in Nigerian Lassa fever patients.
UKE and BNITM receive research funding of 4.5 million euros
Hamburg - It has been increasingly proven that diseases occur with different frequency and run differently in women and men. Now, scientists at the University Medical Center Hamburg-Eppendorf (UKE) and the Bernhard Nocht Institute for Tropical Medicine (BNITM) are researching immunological gender differences so that in future these can be taken into account in the run-up to the treatment of patients. The German Research Foundation (DFG) is funding the project of the research group "Gender-specific Differences in Immune Responses" with 4.5 million euros.
Presenter Yared Dibaba supports "World Day of Neglected Tropical Diseases" on 30 January
Hamburg. Worldwide, almost two billion people are at risk of becoming incapacitated, blind, disfigured, disabled or dying earlier due to neglected tropical diseases. The coronavirus pandemic has exacerbated this danger: many research, treatment and prevention programmes have had to be halted in countries of the global South. The Bernhard Nocht Institute for Tropical Medicine is therefore participating in an international campaign with the aim of not letting up in the fight against neglected tropical diseases - with prominent support.
Till Omansen receives coveted Leibniz funding
The Bernhard Nocht Institute for Tropical Medicine (BNITM) gets the opportunity to establish another junior research group. Dr. Till Omansen from the Department of Clinical Research has been awarded funding from the Leibniz funding programme to establish an independent Junior Research Group. The aim is to research the pathophysiology of Lassa fever. The new transnational group will be based in both the Clinical Research Department and the Virology Department of the BNITM.
Artemisinin-based combination therapy
Are child-friendly, easily soluble tablets or child syrups as effective, safe and tolerable as conventional tablets for malaria therapy? This question was investigated by the Clinical Research Department at the Bernhard Nocht Institute for Tropical Medicine (BNITM) in an elaborate, systematic analysis of available study data, which was published in the Cochrane database this month.
Largest clinical trial for treatment of COVID-19 cases in Africa begins
Hamburg/Kumasi. Thirteen African countries and an international network of research institutions have jointly established a study platform to be able to conduct clinical trials for early treatment of COVID-19 disease. The Kumasi Centre for Collaborative Research (KCCR) in Ghana is also participating in the trial in cooperation with the Bernhard Nocht Institute for Tropical Medicine (BNITM).
TROPICSAFE e-learning platform launched for the safe use of personal protective equipment for infectious diseases
How can healthcare professionals safely transport people with infectious diseases such as COVID-19 or highly pathogenic pathogens such as Ebola? What do you have to consider when handling personal protective equipment (PPE)? This can now be learned on the freely available electronic training platform TROPICSAFE.